SEARCH

SEARCH BY CITATION

References

  • 1
    Dickson M, Jacobzone S. Pharmaceutical use and expenditure for cardiovascular disease and stroke: a study of 12 OECD countries. OECD Health Working Paper 2003;1:179.
  • 2
    PRAIS-UK Investigators. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J 2001;21:14507.
  • 3
    Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:160110.
  • 4
    Fox KA, Goodman SG, Anderson FA, et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. Euro Heart. J 2003;24:141424.
  • 5
    Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome. Eur Heart. J 2002;23:117789.
  • 6
    The VALIANT Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular disease, or both. N Engl J Med 2003;349:1893906.
  • 7
    Struthers A, Anderson G, MacFadyen R, et al. Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assays. Heart 1999;82:5848.
  • 8
    Microsoft. Excel 2000. Available from: http://www.microsoft.com/uk/office/excel/[Accessed March 6, 2008.
  • 9
    The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:66977.
  • 10
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:8218.
  • 11
    Kober L, Torp-Pedersen C, Carlsen J, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:16706.
  • 12
    Flather M, Yusuf S, Kober L, et al. Long-term ACE inhibitor therapy in patients with heart failure of left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:157581.
  • 13
    Tsevat J, Goldman L, Soukup J, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993;13:1615.
  • 14
    Tengs T, Lin T. A meta-analysis of quality of life estimates for stroke. Pharmacoeconomics 2003;21:191200.
  • 15
    Kuntz K, Tsevat J, Goldman L, Weinstein M. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 1996;94:95765.
  • 16
    Department of Health. NHS Reference Costs 2004–2005. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4105545[Accessed March 6, 2008].
  • 17
    Scottish Medicines Consortium. Guidance to Manufacturers: Notes for the Completion of the New Product Assessment Form, 2004.
  • 18
    National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. Available from: http://www.nice.org.uk/page.aspx?o=201973[Accessed February 2, 2006.
  • 19
    Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995;26:91419.
  • 20
    Martinez C, Ball S. Cost-effectiveness of ramipril therapy for patients with clinical evidence of heart failure after acute myocardial infarction. Br J Clin Pract 1995;(Suppl. 78):S2632.
  • 21
    Fox KA, Cokkinos DV, Deckers J, et al. The ENACT study: a pan-European survey of acute coronary syndromes. Eur Heart J 2000;21:14409.
  • 22
    British Cardiovascular Intervention Society. BCIS Audit Returns 2001. Available from: http://www.bcis.org.uk/audit/audit2001[Accessed November 11, 2003.
  • 23
    Grover S, Coupal L, Zowall H, et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:4550.
  • 24
    Curtis L, Netten A. Unit Costs of Health and Social Care 2005, 2005.
  • 25
    British Medical Association RPSoGB. British National Formulary 55. London: Royal Pharmaceutical Society of Great Britain, 2005.